Recent Updates
Recently added Catalysts
HROW Positive Sentiment

Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026

Key Takeaway: Harrow (Nasdaq: HROW) announced it will report its third quarter financial results on November 9, 2026, after market close. A conference call will follow on November 10, 2026, at 8:00 a.m. ET to discuss the results. The company focuses on ophthalmic disease management solutions in North America.

Market Sentiment Analysis

POSITIVE FACTORS

  • Harrow will report third quarter financial results soon.
  • The company is committed to enhancing patient compliance.
  • Harrow offers a comprehensive portfolio of ophthalmic products.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+67%
120-day peak, hindsight
Typical move
9.5%
average across 5 past catalysts
Cash runway
~23 mo
Low dilution risk
Lead asset
TRIESENCE
Phase 3 · Postoperative Ocular Inflammation

Full Press Release Details

NASHVILLE, Tenn., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the third quarter ended September 30, 2026, on Monday, November 9, 2026, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, November 10, 2026, to discuss the results and provide a business update.
Conference Call Information Participants can access the live webcast of Harrow’s presentation on the “Investors” page of Harrow’s website. A replay of the webcast will be available on the Company’s website for one year.
To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, for accessing the call.
About Harrow Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

Contact: Mike Biega VP of Investor Relations & Communications mbiega@harrowinc.com 617-913-8890

Frequently Asked Questions

When will Harrow report its Q3 2026 financial results?

Harrow will report its Q3 2026 financial results on November 9, 2026.

What time is Harrow's conference call?

The conference call is scheduled for 8:00 a.m. ET on November 10, 2026.

Where can I find the webcast of the presentation?

The webcast will be available on the 'Investors' page of Harrow's website.

What products does Harrow offer?

Harrow provides solutions for various ophthalmic conditions, including dry eye disease.

Last updated: Oct 26, 2026